Prismic Pharmaceuticals, Inc., a USA-based pharmaceutical company, announced in June 2013 that it has completed an exclusive licensing rights to an Italian formulation of Palmitoylethanolamide (PEA), to develop as a novel non-steroidal, kidney-friendly anti-inflammatory and anti-fibrotic agent. The Italian CEO, Raffaella della Valle, pointed out that PEA has been explored in man in various clinical trials in a variety of pain states, for inflammatory and pain syndromes, and has an extremely well-documented safety profile.
The company pointed out that Inflammation and oxidative stress both play a key role in the induction and the progression of Chronic Kidney Disease (CKD). Especially in diabetic patients this is a concern. the company highlighted that and inflammation is most likely a major factor in the pathogenesis and progression of diabetic nephropathy.
Prismic is focussing to support the further clinical development with PEA and to prove the concept that palmitoylethanolamide is a useful therapy in diabetic nephropathy.
The issue with the company follows up has been debated already since years in naturpath circles, that is that by reducing low grade chronic inflammation and by inhibiting oxidative stress, molecules such as PEA may reduce risk factors associated with the progression of Chronic Kidney Disease (CKD).
Especially since PEA is devoid of side effects, and does not use liver or kidney pathways for its metabolism, PEA is a very good candicate for treating inflammation in chronic nephropathy.
Prismic Pharmaceuticals has secured worldwide licensing rights (with the exception of Italy and Spain) for PEA from the Epitech Group SRL, and has rights in all regulatory categories for CKD.